1. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of In vitro Diagnostic Device Evaluation and Safety, Center for Biological Evaluation and Research. ‘Draft Guidance for Industry and Food and Drug Administration Staff: In vitro Companion Diagnostic Devices.’ Retrieved from; 2011 [accessed December 2012].
2. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of In vitro Diagnostic Device Evaluation and Safety, Center for Biological Evaluation and Research. ‘Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: In vitro Diagnostic Multivariate Index Assays.’ Retrieved from; 2007 [accessed December 2012].
3. Department of Health and Human Services, Food and Drug Administration. ‘Drug Diagnostic Co-Development Concept Paper.’ Retrieved from; 2005 [accessed December 2012].
4. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer;Lievre;Cancer Res,2006
5. Pollack A. Medical treatment, out of reach. The New York Times. Retrieved from; 2011 [accessed December 2012].